Global Journal of Science Frontier Research, G: Bio-Tech & Genetics, Volume 22 Issue 2

signaling. Am J Pathol 182, 2015-2027, doi: 10.1016 /j.ajpath.2013.02.035 (2013). 34. Kim, J. H. et al. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. Oncotarget 7, 24549-24558, doi: 10.18632/ oncotarget.8240 (2016). 35. Beird, H. C. et al. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud 4, doi: 10.1101/ mcs.a002386 (2018). 36. Boregowda, S. V. et al. Basal p53 expression is indispensable for mesenchymal stem cell integrity. Cell Death Differ 25, 679-692, doi:10.1038/s41418- 017-0004-4 (2018). 37. Sage, J. The retinoblastoma tumor suppressor and stem cell biology. Genes Dev 26, 1409-1420, doi: 10.1101/gad.193730.112 (2012). 38. Velletri, T. et al. Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin. Cell Death Differ , doi: 10.1038/s41418-020-0590-4 (2020). 39. Calvete, O. et al. The wide spectrum of POT1 gene variants correlates with multiple cancer types. Eur J Hum Genet 25, 1278 -1281, doi: 10.1038/ejhg. 2017.134 (2017). 40. Hirata, K. et al. A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. Am J Gastroenterol 101, 193-196, doi: 10.1111/j.1572-0241.2005.00308.x (2006). 41. Yozu, M. et al. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field. Virchows Arch 462, 355-360, doi:10.1007/s00428-012-1369-x (2013). 42. Butnor, K. J., Pavlisko, E. N., Sporn, T. A. & Roggli, V. L. Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms. Arch Pathol Lab Med 142, 730-734, doi: 10.5858/arpa.2017-0307-OA (2018). 43. Ferreira, M. S. V. et al. Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas. Int J Mol Sci 19, doi: 10.3390/ ijms19020608 (2018). 44. Lee, J. C. et al. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol 28, 1064-1073, doi: 10.1038/modpathol. 2015.67 (2015). 45. Venturini, L., Motta, R., Gronchi, A., Daidone, M. & Zaffaroni, N. Prognostic relevance of ALT- associated markers in liposarcoma: a comparative analysis. BMC Cancer 10, 254, doi: 10.1186/1471- 2407-10-254 (2010). 46. Lawlor, R. T. et al. Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. BMC Cancer 19, 232, doi: 10.1186/s12885-019- 5424-8 (2019). 47. Ren, X., Tu, C., Tang, Z., Ma, R. & Li, Z. Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. Oncol Lett 15, 7489- 7496, doi: 10.3892/ol.2018.8318 (2018). 48. Costa, A. et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66, 8918-8924, doi: 10.1158/0008-5472.CAN-06-0273 (2006). 49. Toro, J. R. et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 119, 2922-2930, doi: 10.1002/ijc.22239 (2006). 50. Baird, K. et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65, 9226-9235, doi: 10.1158/0008-5472.CAN- 05-1699 (2005). 51. Dal Cin, P., Sciot, R., De Wever, I., Van Damme, B. & Van den Berghe, H. New discriminative chromosomal marker in adipose tissue tumors. The chromosome 8q11-q13 region in lipoblastoma. Cancer Genet Cytogenet 78, 232-235, doi: 10.1016/ 0165-4608(94)90095-7 (1994). 52. Gisselsson, D. et al. PLAG1 alterations in lipoblastoma: involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am J Pathol 159, 955-962, doi: 10.1016/S0002-9440(10)61771-3 (2001). 53. Mrozek, K., Karakousis, C. P. & Bloomfield, C. D. Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3. Cancer Res 53, 1670-1675 (1993). 54. Kanojia, D. et al. Identification of somatic alterations in lipoma using whole exome sequencing. Sci Rep 9, 14370, doi:10.1038/s41598-019-50805-w (2019). 55. Amin-Mansour, A. et al. Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clin Cancer Res 25, 5135-5142, doi: 10.1158/1078- 0432.CCR-19-0271 (2019). 56. Rosai, J. et al. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol 20, 1182-1189 (1996). 57. Coindre, J. M., Pedeutour, F. & Aurias, A. Well- differentiated and dedifferentiated liposarcomas. © 2022 Global Journals 1 Year 2022 28 Global Journal of Science Frontier Research Volume XXII Issue ersion I VII ( G ) The Genomics of Liposarcoma: A Review and Commentary